BIOSYENT INC (RX.CA) Fundamental Analysis & Valuation

TSX-V:RX • CA0906901081

15.5 CAD
-0.15 (-0.96%)
Last: Mar 5, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

8

RX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. RX gets an excellent profitability rating and is at the same time showing great financial health properties. RX is growing strongly while it is still valued neutral. This is a good combination! This makes RX very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

9

1. RX.CA Profitability Analysis

1.1 Basic Checks

  • In the past year RX was profitable.
  • In the past year RX had a positive cash flow from operations.
  • In the past 5 years RX has always been profitable.
  • Each year in the past 5 years RX had a positive operating cash flow.
RX.CA Yearly Net Income VS EBIT VS OCF VS FCFRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

1.2 Ratios

  • With an excellent Return On Assets value of 18.07%, RX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • The Return On Equity of RX (21.64%) is better than 94.12% of its industry peers.
  • With an excellent Return On Invested Capital value of 20.81%, RX belongs to the best of the industry, outperforming 97.06% of the companies in the same industry.
  • RX had an Average Return On Invested Capital over the past 3 years of 16.58%. This is significantly above the industry average of 8.25%.
  • The 3 year average ROIC (16.58%) for RX is below the current ROIC(20.81%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 18.07%
ROE 21.64%
ROIC 20.81%
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
RX.CA Yearly ROA, ROE, ROICRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

  • With an excellent Profit Margin value of 20.47%, RX belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
  • RX's Profit Margin has been stable in the last couple of years.
  • RX has a Operating Margin of 26.75%. This is amongst the best in the industry. RX outperforms 88.24% of its industry peers.
  • RX's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 77.46%, RX belongs to the top of the industry, outperforming 97.06% of the companies in the same industry.
  • In the last couple of years the Gross Margin of RX has remained more or less at the same level.
Industry RankSector Rank
OM 26.75%
PM (TTM) 20.47%
GM 77.46%
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
RX.CA Yearly Profit, Operating, Gross MarginsRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

10

2. RX.CA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), RX is creating value.
  • The number of shares outstanding for RX has been reduced compared to 1 year ago.
  • RX has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, RX has an improved debt to assets ratio.
RX.CA Yearly Shares OutstandingRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
RX.CA Yearly Total Debt VS Total AssetsRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • An Altman-Z score of 16.89 indicates that RX is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 16.89, RX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • RX has a debt to FCF ratio of 0.11. This is a very positive value and a sign of high solvency as it would only need 0.11 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.11, RX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • A Debt/Equity ratio of 0.02 indicates that RX is not too dependend on debt financing.
  • RX's Debt to Equity ratio of 0.02 is fine compared to the rest of the industry. RX outperforms 79.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.11
Altman-Z 16.89
ROIC/WACC2.43
WACC8.57%
RX.CA Yearly LT Debt VS Equity VS FCFRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.3 Liquidity

  • RX has a Current Ratio of 5.06. This indicates that RX is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 5.06, RX belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
  • A Quick Ratio of 4.23 indicates that RX has no problem at all paying its short term obligations.
  • RX's Quick ratio of 4.23 is amongst the best of the industry. RX outperforms 94.12% of its industry peers.
Industry RankSector Rank
Current Ratio 5.06
Quick Ratio 4.23
RX.CA Yearly Current Assets VS Current LiabilitesRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. RX.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 24.84% over the past year.
  • RX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.02% yearly.
  • RX shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.22%.
  • The Revenue has been growing by 10.33% on average over the past years. This is quite good.
EPS 1Y (TTM)24.84%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%19.41%
Revenue 1Y (TTM)22.22%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%27.9%

3.2 Future

  • RX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.80% yearly.
  • Based on estimates for the next years, RX will show a quite strong growth in Revenue. The Revenue will grow by 11.07% on average per year.
EPS Next Y20.96%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
EPS Next 5YN/A
Revenue Next Year23.16%
Revenue Next 2Y12.62%
Revenue Next 3Y11.07%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RX.CA Yearly Revenue VS EstimatesRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
RX.CA Yearly EPS VS EstimatesRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.2 0.4 0.6 0.8

More info and screens

Find the best growth stocksShow best growing peers

5

4. RX.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 25.00, which means the current valuation is very expensive for RX.
  • 70.59% of the companies in the same industry are more expensive than RX, based on the Price/Earnings ratio.
  • RX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.74.
  • The Price/Forward Earnings ratio is 17.47, which indicates a rather expensive current valuation of RX.
  • Based on the Price/Forward Earnings ratio, RX is valued a bit cheaper than the industry average as 70.59% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of RX to the average of the S&P500 Index (24.82), we can say RX is valued slightly cheaper.
Industry RankSector Rank
PE 25
Fwd PE 17.47
RX.CA Price Earnings VS Forward Price EarningsRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RX is on the same level as its industry peers.
  • RX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. RX is cheaper than 70.59% of the companies in the same industry.
Industry RankSector Rank
P/FCF 22.02
EV/EBITDA 12.03
RX.CA Per share dataRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3

4.3 Compensation for Growth

  • RX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of RX may justify a higher PE ratio.
  • A more expensive valuation may be justified as RX's earnings are expected to grow with 15.80% in the coming years.
PEG (NY)1.19
PEG (5Y)1.66
EPS Next 2Y19.25%
EPS Next 3Y15.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. RX.CA Dividend Analysis

5.1 Amount

  • RX has a Yearly Dividend Yield of 1.34%.
  • RX's Dividend Yield is rather good when compared to the industry average which is at 0.37. RX pays more dividend than 91.18% of the companies in the same industry.
  • RX's Dividend Yield is slightly below the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 1.34%

5.2 History

  • RX has been paying a dividend for over 5 years, so it has already some track record.
  • The dividend of RX decreased in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years2
RX.CA Yearly Dividends per shareRX.CA Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.05 0.1 0.15

5.3 Sustainability

  • RX pays out 25.51% of its income as dividend. This is a sustainable payout ratio.
DP25.51%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
RX.CA Yearly Income VS Free CF VS DividendRX.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
RX.CA Dividend Payout.RX.CA Dividend Payout, showing the Payout Ratio.RX.CA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

RX.CA Fundamentals: All Metrics, Ratios and Statistics

BIOSYENT INC

TSX-V:RX (3/5/2026, 7:00:00 PM)

15.5

-0.15 (-0.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-20
Earnings (Next)03-18
Inst Owners3.68%
Inst Owner ChangeN/A
Ins Owners17.83%
Ins Owner ChangeN/A
Market Cap177.94M
Revenue(TTM)42.18M
Net Income(TTM)8.63M
Analysts82.86
Price Target16.83 (8.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.34%
Yearly Dividend0.18
Dividend Growth(5Y)N/A
DP25.51%
Div Incr Years2
Div Non Decr Years2
Ex-Date02-27
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)22.22%
PT rev (3m)26.92%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.81%
Valuation
Industry RankSector Rank
PE 25
Fwd PE 17.47
P/S 4.22
P/FCF 22.02
P/OCF 21.86
P/B 4.46
P/tB 5.09
EV/EBITDA 12.03
EPS(TTM)0.62
EY4%
EPS(NY)0.89
Fwd EY5.73%
FCF(TTM)0.7
FCFY4.54%
OCF(TTM)0.71
OCFY4.57%
SpS3.67
BVpS3.48
TBVpS3.04
PEG (NY)1.19
PEG (5Y)1.66
Graham Number6.96
Profitability
Industry RankSector Rank
ROA 18.07%
ROE 21.64%
ROCE 27.74%
ROIC 20.81%
ROICexc 48.97%
ROICexgc 68.62%
OM 26.75%
PM (TTM) 20.47%
GM 77.46%
FCFM 19.16%
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
ROICexc(3y)59.42%
ROICexc(5y)88.26%
ROICexgc(3y)72.91%
ROICexgc(5y)116.75%
ROCE(3y)22.1%
ROCE(5y)21.86%
ROICexgc growth 3Y-33.84%
ROICexgc growth 5Y-15.21%
ROICexc growth 3Y-35.8%
ROICexc growth 5Y-16.72%
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
F-Score7
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.11
Debt/EBITDA 0.06
Cap/Depr 6.81%
Cap/Sales 0.14%
Interest Coverage 217.41
Cash Conversion 67.01%
Profit Quality 93.59%
Current Ratio 5.06
Quick Ratio 4.23
Altman-Z 16.89
F-Score7
WACC8.57%
ROIC/WACC2.43
Cap/Depr(3y)10.2%
Cap/Depr(5y)10.36%
Cap/Sales(3y)0.16%
Cap/Sales(5y)0.17%
Profit Quality(3y)95.24%
Profit Quality(5y)108.02%
High Growth Momentum
Growth
EPS 1Y (TTM)24.84%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%19.41%
EPS Next Y20.96%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
EPS Next 5YN/A
Revenue 1Y (TTM)22.22%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%27.9%
Revenue Next Year23.16%
Revenue Next 2Y12.62%
Revenue Next 3Y11.07%
Revenue Next 5YN/A
EBIT growth 1Y37.32%
EBIT growth 3Y3.2%
EBIT growth 5Y7.32%
EBIT Next Year39.54%
EBIT Next 3Y16.91%
EBIT Next 5YN/A
FCF growth 1Y22.97%
FCF growth 3Y23.38%
FCF growth 5Y17.21%
OCF growth 1Y24.46%
OCF growth 3Y22.83%
OCF growth 5Y14.5%

BIOSYENT INC / RX.CA FAQ

What is the fundamental rating for RX stock?

ChartMill assigns a fundamental rating of 8 / 10 to RX.CA.


What is the valuation status for RX stock?

ChartMill assigns a valuation rating of 5 / 10 to BIOSYENT INC (RX.CA). This can be considered as Fairly Valued.


What is the profitability of RX stock?

BIOSYENT INC (RX.CA) has a profitability rating of 9 / 10.


What is the valuation of BIOSYENT INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BIOSYENT INC (RX.CA) is 25 and the Price/Book (PB) ratio is 4.46.


Can you provide the dividend sustainability for RX stock?

The dividend rating of BIOSYENT INC (RX.CA) is 4 / 10 and the dividend payout ratio is 25.51%.